SPECTRANETICS CORP (SPNC) [Rocket]

Date Filed	Type	Description
08/10/2017	GN	Spectranetics Announces Fundamental Change, Make-Whole Adjustment Event, Share Exchange Event and Supplemental Indenture for 2.625% Convertible Senior Notes due 2034
08/03/2017	GN	Spectranetics Reports Second Quarter 2017 Revenue of $74.7 million
07/26/2017	GN	Spectranetics Announces FDA Approval of Stellarex™ Drug-Coated Balloon
07/13/2017	GN	Spectranetics Announces Second Quarter Earnings Release Date
06/28/2017	GN	Philips to acquire The Spectranetics Corporation to accelerate expansion in image-guided therapy devices to treat cardiac and peripheral vascular disease
06/09/2017	GN	Spectranetics Announces $140 Million Debt Refinancing
05/11/2017	GN	Healthcare Veteran John Fletcher Joins MRI Interventions' Board of Directors
05/11/2017	GN	Healthcare Veteran John Fletcher Joins MRI Interventions' Board of Directors
04/07/2017	GN	Spectranetics Announces First Quarter 2017 Conference Call
02/23/2017	GN	Spectranetics Reports Fourth Quarter 2016 Revenue of $71.9 million
02/02/2017	GN	Spectranetics Announces Fourth Quarter 2016 Conference Call
10/08/2012	GN	Spectranetics Announces U.S. Launch of the TAPAS(TM) Catheter and Preclinical Animal Data on Drug Uptake in Peripheral Vessels
08/23/2012	GN	Spectranetics to Participate in Upcoming Investor Conferences
07/26/2012	GN	Spectranetics Achieves Second Quarter Revenue of $35.0 Million
07/18/2012	GN	Spectranetics to Hold 2012 Second Quarter Financial Results Conference Call on July 26
07/12/2011	BW	Spectranetics Appoints Scott Drake as President and Chief Executive Officer
05/31/2011	BW	Spectranetics Introduces First Advanced System for Simulation of Peripheral Vascular Arterial Occlusions
04/19/2011	BW	Spectranetics to Hold 2011 First Quarter Financial Results Conference Call on April 27
04/06/2011	BW	Spectranetics Announces Approval of LLD in Japan
02/17/2011	BW	Spectranetics Reports Fourth Quarter Revenue of $29.3 Million, in Line with Previous Guidance
11/30/2010	BW	Spectranetics to Present at the 5th Annual Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference on December 7
11/10/2010	BW	Spectranetics to Present at the Citi Small/Mid Cap Conference on November 17
11/03/2010	BW	Spectranetics Appoints Maria Sainz and Daniel A. Pelak as Independent Directors
10/27/2010	BW	Spectranetics Reports Third Quarter Revenue of $29.6 Million